Just after the French ranking by Les ECHOS, TransCure bioServices is ranked 666 in the TOP 1000 European companies by THE FINANCIAL TIMES!
TransCure bioServices is recognized as one of the “most nimble and innovative companies” in Europe.
The FINANCIAL TIMES just published its ranking, based on the Revenue CAGR 2015-2018. New in the list, TransCure bioServices is ranked 666, with absolute revenue growth of 250,5% and a revenue CAGR of 51,9%. Only 8 companies are listed in the pharmaceutical sector, and our sustained growth in 2019 will also be recognized at the next year’s ranking.
Our dedicated team expert in full human immune system is working hard to stay in the run.
See the ranking from THE FINANCIAL TIMES